Lilly diabetes drug wins approval for expanded use
Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s Byetta has received expanded approval for use with the world’s top-selling insulin to treat Type 2 diabetes.
Health Care & Insurance
Articles
Ex-Dow Agro scientist pleads guilty in espionage case
Kexue Huang faces up to 13 years in prison after pleading guilty Tuesday morning to sending trade secrets worth millions to China and Germany.
Judge slaps IU Health over billing
The Indiana Court of Appeals reversed a Marion Superior Court decision to dismiss a lawsuit by two uninsured patients who received care at IU Health North Hospital in Carmel.
Deficit committee could bite CNO
Medicare supplement policies are reportedly one of the targets of Congress’ special deficit-reduction committee—and that’s not good news for Carmel-based CNO Financial Group Inc.
IU workers to see spike in health insurance costs
An IU official said premiums continue to rise and the university can't continue matching the amount of the increase.
Cook Medical gets FDA panel’s backing for stent
The device would be the first drug-coated stent approved in the U.S. to treat peripheral vascular disease in the largest artery of the upper leg.
Bostech’s software aims to rein in lab-test costs
The company saw sales surge after introducing software in May that helps medical labs manage their disparate computer systems from a Web portal.
FDA: Cook Medical’s stent met efficacy, safety goals
Peripheral vascular devices, including stents, angioplasty balloons and synthetic grafts, generated $4.3 billion in global revenue last year and may earn $5.6 billion in 2014.
Lilly announces replacements for two retiring executives
Bryce Carmine, president of Lilly’s bio-medicines division, and Frank Deane, president of Lilly’s global manufacturing operations, both will retire on Dec. 31.
IU Alzheimer’s study to be funded by $8.4M federal grant
Remaining grant money will be invested to beef up the infrastructure of the Indiana Network for Patient Care, a health information exchange operated by the Indianapolis-based Regenstrief Institute.
Lilly gets dinged for job cuts
Eli Lilly and Co. got called out in a recent report on companies that took advantage of the 2004 tax holiday on foreign profits and have since slashed jobs.
Best and worst of times for new docs
Medical residents are getting more job offers than before, yet greater numbers of them say if they had it to do over again, they would not go to medical school.
FDA approves Cialis for enlarged prostate
Cialis, Lilly’s blockbuster erectile dysfunction drug, now can be taken to treat enlarged prostate. FDA approval means men who suffer from both disorders can take one medication.
Dentist driven to draw blacks to profession
When Jeanette Sabir-Holloway entered dental school at Indiana University in 1976, she was one of only three black students in a class of 120. She would be the only African-American to graduate with her class four years later.
Waiting for construction industry to recover
The recession officially ended more than two years ago. But the number of local construction jobs is still down 27 percent from 2007 levels. Will the industry ever feel relief? Some segments might not recover in a big way until 2013.
Lilly CEO says he’s not interested in Pfizer animal unit
Drugmaker Eli Lilly and Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, CEO John Lechleiter said Wednesday.
Rezoning sought for growing children’s health program
The Children’s Better Health Institute, a division of The Saturday Evening Post Society Inc., plans to ask the Metropolitan Development Commission to rezone a 23-acre parcel on the city’s northwest side.
IU Health, Howard Regional call off merger talks
The integration of the two not-for-profit hospital systems, approved by Howard Regional's board in late May, is now dead, the two hospitals announced Monday.
Eli Lilly, Turkish firm in talks to sell drugs in 26 nations
Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, is in talks with Mustafa Nevzat Ilac Sanayii AS to sell the Turkish company’s treatments in 26 countries, said Mustafa Nevzat’s CEO.